Genovis’ rights issue fully subscribed

Genovis’ rights issue is fully subscribed and 81% of the shares are subscribed
with preferential rights. The rights issue raised about SEK 12.1 million before
issue expenses for Genovis. Statements of account will be sent on May 22, 2012,
to allot shares subscribed without preferential rights.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel:
4646 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis develops and sells innovative technologies from two unique product
portfolios. The first includes enzymes that facilitate development and quality
control for applications such as antibody-based drugs. The products launched to
date are aimed at customers who work with development of drugs, new diagnostic
methods and basic research.

The second consists of nanotechnology in new contrast agents and focuses on
design, production and characterization of nanostructures as contrast agents in
medical imaging. The nanostructures and methods that Genovis focuses on can also
be used as carriers of various substances in the development of new drug
delivery methods. The projects are mainly in-house, but also include
collaborations with research groups, including at Lund University.

Genovis shares are listed on the First North OMX Nordic Exchange and Thenberg
Fondkommission is our certified advisor.